EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER

Background. Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The prognosis of the disease is largely determined by thebiological subtype of the tumor. Her2-positive breast cancer is characterized by an aggressi...

Full description

Bibliographic Details
Main Authors: O. I. Kit, L. Yu. Vladimirova, E. A. Kalabanova, A. E. Storozhakova, S. N. Kabanov, T. A. Snezhko, I. S. Mitashok, Ya. V. Svetitskaya, N. Yu. Samaneva, I. S. Kornilova, Yu. V. Przhedetskiy, V. V. Pozdnyakova, N. A. Abramova, I. L. Popova, N. M. Tikhanovskaya, A. A. Lyanova, K. A. Novoselova, L. A. Ryadinskaya
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2021-05-01
Series:Сибирский онкологический журнал
Subjects:
рак молочной железы
her2-положительный подтип
пертузумаб
прогноз
Online Access:https://www.siboncoj.ru/jour/article/view/1760

Internet

https://www.siboncoj.ru/jour/article/view/1760

Similar Items